Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
GM

NYSE · GMED

Globus Medical, Inc.

Healthcare · Medical - Devices

$79.46

Up+$1.41 (+1.81%)

Updated Nov 3, 2026, 8:31 AM

SID Score

5.7/10

Composite research score

Smart Money

62/100

Neutral

Market cap
11.89B
P/E ratio
28.2
Dividend yield
0.00%
52-week range
$59.51 – $101.40
Volume
1.51M
Avg. volume
1.73M

Price performance · GMED

GMED price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

GMED closed at $79.46 after 21 trading sessions, up 3.77% for the selected period.

Last close
$79.46
Period change
+3.77%
Period low
$73.33
Period high
$82.91
Daily close
View OHLC price history
GMED OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$77.60$80.42$77.60$79.461.51M
Oct 30, 2026$80.80$80.84$77.77$78.051.68M
Oct 29, 2026$82.37$83.4325$81.785$82.91861.91K
Oct 28, 2026$80.47$81.75$80.2289$81.26772.42K
Oct 27, 2026$81.53$82.015$80.06$80.90634.84K
Oct 26, 2026$81.50$81.91$80.625$81.831.03M
Oct 23, 2026$81.06$82.0133$80.4001$81.41768.46K
Oct 22, 2026$79.54$81.83$78.46$81.661.29M
Oct 21, 2026$78.02$79.95$77.96$78.681.03M
Oct 20, 2026$76.57$79.20$76.17$78.961.55M
Oct 19, 2026$76.12$76.70$75.43$75.651.26M
Oct 16, 2026$79.35$79.95$76.49$76.711.94M
Oct 15, 2026$77.66$79.28$77.05$78.841.84M
Oct 14, 2026$76.57$76.73$75.13$76.311.06M
Oct 13, 2026$76.70$76.71$74.985$76.321.11M
Oct 12, 2026$74.89$76.39$74.61$76.241.1M
Oct 9, 2026$73.90$75.32$73.6845$74.651.08M
Oct 8, 2026$73.48$74.27$72.5432$73.331.89M
Oct 7, 2026$75.56$76.66$73.26$73.752.47M
Oct 6, 2026$77.01$77.6566$75.84$76.431.57M
Oct 5, 2026$75.60$77.17$75.0308$76.571.61M

Latest GMED news

The latest Smart Investors Daily articles mentioning GMED.

Stock researchCompany · Overview

GMED research

Overview

Company profile and research snapshot.

Company profile

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$76.00
Implied upside
—
Analysts
—
GMED recent ratings
DateFirmRatingTarget
Oct 1, 2026RBC CapitalOutperform—
Aug 7, 2026Wells FargoOverweight—
Jul 28, 2026UBSNeutral—
Jul 16, 2026Truist SecuritiesBuy—
Jul 13, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 27, 2026

Globus Medical Record Q4 And Synergies Refocus Valuation And Growth Debate

Globus Medical (NYSE:GMED) reported record Q4 and full year results, supported by its U.S. Spine and Trauma businesses and Enabling Technologies segment. The company completed integrations of NuVasive and Nevro, with NuVasive synergies reaching $200 million nearly a year ahead of the original timetable. Globus Medical repaid acquired convertible debt and signaled plans to increase R&D and product development investment. For context, Globus Medical shares most recently traded at $96.71. The...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By